Results 11 to 20 of about 2,270 (113)

Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome:pairwise and network meta-analysis of randomized trials [PDF]

, 2021
OBJECTIVE: Combined oral contraceptives are often considered a treatment option for women with premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD) also seeking contraception, but evidence for this treatment is scarce.
DE Boer, Marrit K, DE Vries, Ymkje Anna, DE Wit, Anouk E, Fokkema, Ante, Giltay, Erik J, Janssen, Catharina Ah, Scheper, Celeste, Schoevers, Robert A   +7 more
core   +2 more sources

A chewable low-dose oral contraceptive: a new birth control option? [PDF]

, 2012
A new chewable combined oral contraceptive pill containing ethinyl estradiol (EE) 0.025 mg and norethindrone (NE) 0.8 mg in a 24/4 regimen was approved for marketing in December 2010.
Weisberg, Edith
core   +4 more sources

Evaluation of the effect of aromatase inhibitor in reducing the size of endometrioma [PDF]

, 2021
Background: Endometriosis is a chronic and progressive estrogen-dependent disorder that can result in substantial morbidity, including pelvic pain, multiple operations, and infertility.
Afrin, Shajia, Ansary, Selina Afroz, Banu, Jesmine, Fatima, Parveen, Ishrat, Shakeela, Jahan, Israt, Mohsin, Mohammad, Nasreen, Faria, Nasreen, Khaleda   +8 more
core   +2 more sources

Nestorone® as a Novel Progestin for Nonoral Contraception:Structure-Activity Relationships and Brain Metabolism Studies [PDF]

, 2017
Nestorone® (NES) is a highly potent non-androgenic progestin being developed for contraception. NES is a synthetic progestin that may possess neuroprotective and myelin regenerative potential as an added health benefits.
Alanah R. Knibb, Attardi, Belelli, Belelli, Brinton, Brown, Brown, Callachan, Celotti, Davies, El-Etr, Gago, Garay, Haukkamaa, Heikinheimo, Heikinheimo, Hussain, Isabelle Petit-Topin, Jeremy J. Lambert, Jerôme Fagart, Kumar, Lambert, Lambert, Liere, Liu, Liu, Lähteenmäki, Marie-Edith Rafestin-Oblin, Marion Rame, Martine El-Etr, Matias, Meffre, Michael Schumacher, Narender Kumar, Noé, Pereira de Jésus-Tran, Petit-Topin, Petit-Topin, Philippe Liere, Regine Sitruk-Ware, Schumacher, Schüle, Scott J. Mitchell, Sitruk-Ware, Sitruk-Ware, Sitruk-Ware, Sivin, Stanczyk, Tuba, Williams, Winneker, Wong   +51 more
core   +2 more sources

The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin. Part I [PDF]

, 1985
Poly(α-l-glutamic acid) (PGA) was grafted with amino acid and oligopeptide spacers up to 5 amino acids with the use of N,N'-carbonyldiimidazole and 2,3-dihydro-1,2-benz-isothiazole-3-on-1, 1-dioxide (saccharin) as an additive, and these polypeptides were
Eenink, M.J.D., Feijen, J., Heeswijk, W.A.R., Hoes, C.J.T., Potman, W., Stoffer, T.   +5 more
core   +2 more sources

Acute exogenous oestradiol augments endothelial and smooth muscle vasodilatory responsiveness in premenopausal but not postmenopausal females

The Journal of Physiology, Volume 603, Issue 8, Page 2301-2311, 15 April 2025.
Abstract figure legend Brachial intraarterial infusion of exogenous 17β‐oestradiol augmented endothelial and smooth muscle microvascular vasodilatation in premenopausal but not postmenopausal, females. Abstract Menopause is associated with vascular dysfunction. During the menopausal transition, endogenous oestradiol concentrations diminish.
Gabrielle A. Dillon, Ronée E. Harvey, Jacqueline K. Limberg, Wayne T. Nicholson, Michael J. Joyner, Sarah E. Baker, Virginia M. Miller, Sushant M. Ranadive   +7 more
wiley   +1 more source

Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies

The Journal of Clinical Pharmacology, Volume 65, Issue 5, Page 598-606, May 2025.
Abstract Mavacamten is a potential inducer of cytochrome P450 (CYP) 3A4 and could reduce the effectiveness of concomitant drugs that are metabolized by CYP3A4, such as midazolam. This study aimed to determine if repeat doses of mavacamten achieving clinically relevant exposures affected midazolam exposure.
Samira Merali, Caroline Sychterz, Vidya Perera, Lu Gaohua, Victoria Florea, Bindu Murthy   +5 more
wiley   +1 more source

Hormonal content and potency of oral contraceptives and breast cancer risk among young women [PDF]

, 2003
A small study of women with early-onset breast cancer published in 1983 initially sparked the debate about combination oral contraceptives and breast cancer by suggesting that a woman's risk of breast cancer increased if she used oral contraceptives ...
Althuis, M D, Brinton, L A, Brogan, D R, Coates, R J, Daling, J R, Gammon, M D, Malone, K E, Schoenberg, J B   +7 more
core   +3 more sources

Recent Developments in Deep Eutectic Solvents Applications in Liquid Chromatography: 2019–2025

Journal of Separation Science, Volume 48, Issue 5, May 2025.
ABSTRACT Deep eutectic solvents (DES) are used as mobile phase and stationary phase modifiers, or as for the stationary phase itself for thin layer/liquid/supercritical chromatography. Their specific properties can improve the separation selectivity, reduce peak tailing, and shorten the separation time.
Derya Demir, Joanna Antos, František Švec, Hana Sklenářová   +3 more
wiley   +1 more source

Effectiveness and acceptability of progestogens in combined oral contraceptives – a systematic review [PDF]

, 2004
BACKGROUND: The progestogen component of oral contraceptives (OCs) has undergone changes since it was recognized that their chemical structure can influence the spectrum of minor adverse and beneficial effects.
A Metin Gülmezoglu, ACOG Technical Bulletin, D Serfaty, D Shoupe, F Weber-Diehl, Frans M Helmerhorst, Gestodene Study Group, H Smith, HW Halbe, IH Thorneycroft, J Endrikat, J Endrikat, J Huber, JM Foidart, L Speroff, L Speroff, L Zichella, Latin American Oral Contraceptive Study Group, M Singh, MJ Rosenberg, MR Henzl, Nandita Maitra, NB Loudon, P Affinito, PJ Hilllard, R Ramos, Regina Kulier, RKL Percival-Smith, S Koetsawang, SL Reiter, T Rabe, TR Dunson, U Lachnit-Fixon, W Droegemueller, WG Rossmanith   +34 more
core   +3 more sources